VanEck Associates
TMDX icon

VanEck Associates’s Transmedics TMDX Stock Holding History

VanEck Associates’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Buy
2,072
+288
+16% +$37.6K ﹤0.01% 1262
2025
Q4 		$217K Buy
1,784
+538
+43% +$67.5K ﹤0.01% 1275
2025
Q3 		$140K Buy
1,246
+333
+36% +$39K ﹤0.01% 1306
2025
Q2 		$122K Sell
913
-1,100
-55% -$121K ﹤0.01% 1290
2025
Q1 		$135K Buy
2,013
+16
+0.8% +$1.1K ﹤0.01% 1259
2024
Q4 		$125K Buy
1,997
+1,010
+102% +$94K ﹤0.01% 1264
2024
Q3 		$117K Sell
987
-192
-16% -$29.6K ﹤0.01% 1244
2024
Q2 		$178K Sell
1,179
-584
-33% -$70K ﹤0.01% 1198
2024
Q1 		$130K Buy
1,763
+175
+11% +$14.4K ﹤0.01% 1221
2023
Q4 		$125K Sell
1,588
-539
-25% -$32.5K ﹤0.01% 1213
2023
Q3 		$116K Buy
2,127
+597
+39% +$43K ﹤0.01% 1214
2023
Q2 		$128K Buy
+1,530
New +$117K ﹤0.01% 1210

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates's TMDX Position: Q1 2026 in Review

VanEck Associates increased its Transmedics (TMDX) stake by 16% in Q1 2026, buying an estimated $37.6K and bringing the position to 2,072 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

VanEck Associates first reported a position in TMDX in Q2 2023 and has held it in 12 quarters since. The position peaked at $217K in Q4 2025. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

  • VanEck Associates held 2,072 shares of Transmedics worth $206K as of Q1 2026.
  • VanEck Associates bought 288 Transmedics shares in Q1 2026, an estimated $37.6K.
  • Transmedics made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #1262 holding.
  • VanEck Associates first reported a position in Transmedics in Q2 2023 and has held it in 12 quarters since.
  • VanEck Associates's Transmedics position peaked at $217K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.